SCHEMBL29100770

SCHEMBL29100770

COc1cc(NC=C2C(=O)OC(C)(C)OC2=O)cnc1F

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 18/20 0.56
HSD17B10 Q99714 4/20 0.56
MAPK1 P28482 1/20 0.56
TSHR P16473 1/20 0.56
CASP1 P29466 2/20 0.51
CASP7 P55210 2/20 0.51
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
KMT2A Q03164 1/20 0.44
RAB9A P51151 1/20 0.43
HPGD P15428 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.39
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29701577 0.89 ALDH1A1 (0.57) ALDH1A1HSD17B10MAPK1TSHRCASP1
SCHEMBL29100739 0.89 ALDH1A1 (0.57) ALDH1A1HSD17B10MAPK1TSHRCASP1
SCHEMBL6250003 0.80 ALDH1A1 (0.62) ALDH1A1HSD17B10MAPK1TSHRCASP1
SCHEMBL29487159 0.80 ALDH1A1 (0.62) ALDH1A1HSD17B10MAPK1TSHRCASP1
SCHEMBL27180184 0.79 ALDH1A1 (0.57) ALDH1A1HSD17B10MAPK1TSHRCASP1
SCHEMBL2209684 0.78 ALDH1A1 (0.67) ALDH1A1HSD17B10MAPK1TSHRCASP1
SCHEMBL374339 0.78 ALDH1A1 (0.67) ALDH1A1HSD17B10MAPK1TSHRCASP1
SCHEMBL25284932 0.78 ALDH1A1 (0.56) ALDH1A1HSD17B10MAPK1TSHRCASP1
SCHEMBL30465757 0.78 ALDH1A1 (0.56) ALDH1A1HSD17B10MAPK1TSHRCASP1
SCHEMBL18451210 0.77 ALDH1A1 (0.58) ALDH1A1HSD17B10MAPK1TSHRCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116981667-A Heterocyclic inhibitors of EGFR and/or HER2 for cancer treatment 蝎子疗法股份有限公司 2023-10-31 CN disclosed
EP-4225445-A2 HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER Scorpion Therapeutics, Inc. (US) 2023-08-16 EP disclosed
WO-2022076831-A2 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. (US) 2022-04-14 WO disclosed